• Je něco špatně v tomto záznamu ?

Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry

M. Vališ, Z. Pavelek, M. Novotný, B. Klímová, J. Šarláková, S. Halúsková, M. Peterka, I. Štětkárová, P. Štourač, J. Mareš, P. Hradílek, R. Ampapa, M. Vachová, E. Recmanová, E. Meluzínová

. 2022 ; 13 (-) : 851426. [pub] 20220418

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017361

Importance: Multiple sclerosis can also affect children. Approximately 3-10% of patients develop multiple sclerosis before the age of 16. Objective: The aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosis who started their treatment with disease-modifying drugs in 2013-2020, with data obtained from the Czech National Registry of patients with multiple sclerosis. Design and Setting: A method of retrospective analysis conducted with 134 pediatric patients with multiple sclerosis was used. Results: The findings reveal that the mean age at the date of the introduction of the first disease-modifying drugs treatment is 15.89 years, and gender does not play any role. In addition, moderate (51.6%) and mild (45.2%) relapses are predominant in these young patients. Seventy five percent of patients will not experience a confirmed progression of the expanded disability status scale within 54.7 months from starting the treatment. Furthermore, the results confirm that the first-choice treatment is interferon beta-a and glatiramer acetate, which is common for adult patients. However, some factors, such as a low efficacy or a lack of tolerance may impact on treatment discontinuation in children. Conclusion: More research should be performed on novel disease-modifying drugs for this target group.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017361
003      
CZ-PrNML
005      
20220720100211.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneur.2022.851426 $2 doi
035    __
$a (PubMed)35518208
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vališ, Martin $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
245    10
$a Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry / $c M. Vališ, Z. Pavelek, M. Novotný, B. Klímová, J. Šarláková, S. Halúsková, M. Peterka, I. Štětkárová, P. Štourač, J. Mareš, P. Hradílek, R. Ampapa, M. Vachová, E. Recmanová, E. Meluzínová
520    9_
$a Importance: Multiple sclerosis can also affect children. Approximately 3-10% of patients develop multiple sclerosis before the age of 16. Objective: The aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosis who started their treatment with disease-modifying drugs in 2013-2020, with data obtained from the Czech National Registry of patients with multiple sclerosis. Design and Setting: A method of retrospective analysis conducted with 134 pediatric patients with multiple sclerosis was used. Results: The findings reveal that the mean age at the date of the introduction of the first disease-modifying drugs treatment is 15.89 years, and gender does not play any role. In addition, moderate (51.6%) and mild (45.2%) relapses are predominant in these young patients. Seventy five percent of patients will not experience a confirmed progression of the expanded disability status scale within 54.7 months from starting the treatment. Furthermore, the results confirm that the first-choice treatment is interferon beta-a and glatiramer acetate, which is common for adult patients. However, some factors, such as a low efficacy or a lack of tolerance may impact on treatment discontinuation in children. Conclusion: More research should be performed on novel disease-modifying drugs for this target group.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pavelek, Zbyšek $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Novotný, Michal $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Klímová, Blanka $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Šarláková, Jana $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Halúsková, Simona $u Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
700    1_
$a Peterka, Marek $u Department of Neurology, Faculty of Medicine, University Hospital Plzen, Charles University, Plzen, Czechia
700    1_
$a Štětkárová, Ivana $u Third Faculty of Medicine, Charles University and Hospital Kralovské Vinohrady, Charles University, Prague, Czechia
700    1_
$a Štourač, Pavel $u Department of Neurology, University Hospital, Masaryk University, Brno, Czechia
700    1_
$a Mareš, Jan $u Department of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czechia
700    1_
$a Hradílek, Pavel $u Clinic of Neurology, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Ampapa, Radek $u Department of Neurology, Hospital of Jihlava, Jihlava, Czechia
700    1_
$a Vachová, Marta $u Department of Neurology, KZ a.s., Hospital Teplice, Teplice, Czechia
700    1_
$a Recmanová, Eva $u Department of Neurology, Tomas Bata Regional Hospital, Zlín, Czechia
700    1_
$a Meluzínová, Eva $u Department of Neurology, Second Faculty of Medicine, Charles University, Prague, Czechia
773    0_
$w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 13, č. - (2022), s. 851426
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35518208 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100206 $b ABA008
999    __
$a ind $b bmc $g 1816555 $s 1168603
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 851426 $e 20220418 $i 1664-2295 $m Frontiers in neurology $n Front. neurol. $x MED00174552
LZP    __
$a Pubmed-20220718
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace